Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus Sintilimab in Advanced Solid Tumors
NCT04427774Phase 1Terminated
- Sponsor
- Innovent Biologics
- Start
- Jun 2020
- Primary completion
- Feb 2021
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of surufatinib and sintilimab in solid tumor, sponsored by Innovent Biologics. Primary endpoint: Safety and Tolerability up to 24 months. Started Jun 2020; status: terminated.
02
Drugs
surufatinibsintilimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04427774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04427774.